June 2007 Oncology News International

Publication
Article

Focus on Hematology

Meta-Analysis Shows Rituximab-Chemo Increases Overall Survival in Indolent/Mantle Cell Lymphoma

Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Pts

Focus on Breast Cancer

Novel PET Tracer Detects Breast Tumors and Mets

Vitamin E-Based Paclitaxel May Be Less Neurotoxic

Removing Stage IV Primary May Cut Mortality

Focus on Lung Cancer

Canfosfamide Boosts Chemotherapy's Benefit in NSCLC

Best Measure of Lung Cancer Screening: Curability or Mortality?

Industry Watch

Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

PEG-SN38 Shows Anti-Tumor Activity in Resistant Models

Cougar Biotechnology Reports Positive Data on CB7630

Focus on Colon Cancer

Colonoscopy With Polyp Removal Reduces Mortality

Surveillance Colonoscopy Guidelines Not Being Followed

Cancer Care & Economics

Virtual Colonoscopy Gaining New Respect as a Sensitive and Cost-Effective CRC Screening Tool

Medicare Reacts to Recent Scrutiny of ESAs

Value-Based Competition Key to Healthcare Reform

Focus on Oncology Nursing

Gastric Ca Registry IDs Those With CDH1 Mutation

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content